Lack of Clinically Relevant Interaction Between Desloratadine and Erythromycin
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (Supplement) , 29-35
- https://doi.org/10.2165/00003088-200241001-00005
Abstract
Objective: To evaluate the bioavailability, cardiac safety and tolerability of desloratadine when given in combination with the CYP3A4 inhibitor erythromycin. Design:A randomised, 2-way crossover,...Keywords
This publication has 11 references indexed in Scilit:
- Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic RhinitisClinical Drug Investigation, 2001
- Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor AntagonistArzneimittelforschung, 2000
- Arrhythmogenic mechanisms of non‐sedating antihistaminesClinical and Experimental Allergy, 1999
- Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and NorastemizoleJournal of Cardiovascular Electrophysiology, 1999
- The current cardiac safety situation with antihistaminesClinical and Experimental Allergy, 1999
- Second-generation antihistamines: The risk of ventricular arrhythmiasClinical Therapeutics, 1999
- Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizoleFEBS Letters, 1996
- Torsades de pointes induced by erythromycin and terfenadineThe American Journal of Emergency Medicine, 1994
- Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycinClinical Pharmacology & Therapeutics, 1992
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987